Company intelligence / Profile preview

Edgeware Computers

Boulder, Colorado, USA

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Their lead candidate, sevasemten (EDG-5506), is designed to protect muscle fibers from contraction-induced damage in patients with Duchenne and Becker muscular dystrophy. The company's platform leverages a muscle-focused drug discovery approach to target specific proteins involved in muscle contraction and relaxation. Edgewise is also expanding its pipeline into cardiac muscle diseases, such as hypertrophic cardiomyopathy.

Therapeutic areas: CardiovascularRare Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Edgeware Computers.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Edgeware Computers.

Explore the full profile